Does health economics have an impact on non-Hodgkin's lymphoma patients' options?

Nucl Med Commun. 2008 Aug;29(8):748-9. doi: 10.1097/MNM.0b013e328300005d.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Iodine Radioisotopes
  • Lymphoma, Non-Hodgkin / economics*
  • Lymphoma, Non-Hodgkin / radiotherapy
  • Radioimmunotherapy
  • Radiopharmaceuticals / economics*
  • Radiopharmaceuticals / therapeutic use
  • Yttrium Radioisotopes

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan
  • tositumomab I-131